GlassScriptPhysician profile
Joann M Olsen
NPI 1316160435
$3,678.18
in general payments reported to CMS, 2019-2025
34 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 89% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $991 · 2020: $175 · 2021: $28.95 · 2022: $89.62 · 2023: $375 · 2024: $976 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,344 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,344.41 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $629.52 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $503.61 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $237.89 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $234.05 | 2019-2024 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $221.86 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $204.39 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $189.86 | 2019-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $166.09 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Allergan, INC. | $151.60 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $123.00 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $109.20 | 2023-2025 | Auvelity |
| Neos Therapeutics, LP | $78.69 | 2020-2024 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $74.24 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $71.53 | 2023-2024 | Uzedy, Austedo Xr |
| Shire North American Group INC | $64.71 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $63.02 | 2022-2025 | Aristada, Lybalvi |
| Bioxcel Therapeutics, INC. | $55.00 | 2024 | Igalmi |
| Almatica Pharma LLC | $54.93 | 2023-2024 | Loreev Xr |
| Corium, LLC | $48.86 | 2023-2024 | Azstarys |
| Owp Pharmaceuticals, INC. | $47.89 | 2019 | |
| Avanir Pharmaceuticals, INC. | $43.77 | 2019 | |
| Novo Nordisk INC | $42.98 | 2024-2025 | Wegovy |
| Jazz Pharmaceuticals INC. | $38.99 | 2022 | |
| Bausch Health US, LLC | $33.38 | 2019-2020 | |
| Livanova USA, INC. | $25.31 | 2023 | Vns Therapy Symmetry Model 8103 Generator |
| Harmony Biosciences LLC | $22.47 | 2020 | |
| Collegium Pharmaceutical, INC. | $21.35 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $18.76 | 2019 | |
| Orexo US, INC. | $17.98 | 2019 | |
| Biogen, INC. | $17.74 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $17.61 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $17.59 | 2019 | |
| Noven Therapeutics, LLC | $16.67 | 2025 | Xelstrym, Secuado |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joann Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.